IEİzZettin Ekinci

İzZettin Ekinci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


İzZettin Ekinci has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kanserde Güncel Konular

    by Ceylan Bozyiğit, Havva Aybek, Esra Çeçen, Seda Beyaz, Tülay Çetkin, Fatma Beril Koçyiğit, Gözde Arkalı, Gözde Viktorya Yolcu Varolgüneş, İzZettin Ekinci

  • Top Cited Papers
    Open Access

    Protective Effects of Chrysin Against Diclofenac‐Induced Nephrotoxicity in Rats via Attenuation of Oxidative Stress, Apoptosis and Endoplasmic Reticulum Stress

    by Cuneyt Caglayan, İzZettin Ekinci, Cihan Gur, Adnan Ayna, İbRahim Bayav, Fatih Mehmet Kandemir

    Diclofenac (DCL) is a broadly prescribed non‐steroidal anti‐inflammatory drug (NSAID) for pain management and has been linked to nephrotoxicity despite its therapeutic benefits. This study provides new insights into the palliative impacts of chrysin (CH) against DCL‐induced kidney damage by modulating oxidative injury, endoplasmic reticulum (ER) stress and apoptosis. The rats were divided into five groups: the control group (Group 1), CH‐only group (50 mg/kg, Group 2), DCL‐only group (50 mg/kg, Group 3), DCL + CH (25 mg/kg, Group 4), and DCL + CH (50 mg/kg, Group 5). DCL injection led to significant renal damage marked by elevated serum urea, creatinine and malondialdehyde (MDA) levels, reduced glutathione (GSH) concentration, and decreased activities of antioxidant enzymes (glutathione peroxidase, superoxide dismutase and catalase). The mRNA expression levels of Ho‐1 and Nrf2 were also suppressed. Additionally, DCL treatment triggered apoptosis as evidenced by increased expression of Bax and caspase‐3 alongside decreased Bcl‐2 expression. Furthermore, DCL induced ER stress was confirmed by upregulation of Perk , Ire1 , Atf‐6 , and Grp78 transcription levels. Also, it was demonstrated that DCL treatment upregulated Mmp2 and Mmp9 levels. Treatment with CH significantly mitigated these adverse effects suggesting that CH effectively protects DCL‐induced kidney toxicity by targeting multiple pathways. In summary, this study highlights the importance of CH as a promising therapeutic agent for alleviating kidney damage associated with DCL toxicity.


  • Caregiving Burden of Caregivers of Hemodialysis Patients and Related Factors

    by Rukiye Demi̇r Di̇kmen, Veysel Kizilarslan, İzzettin Eki̇nci̇, Mahmut Çoban

    Objective: This study was conducted to evaluate the caregiving burden of caregivers of patients receiving Hemodialysis (HD) treatment. Methods: The research was conducted with 107 caregivers of patients receiving HD treatment at State Hospital and Private Dialysis Center. The entire population was intended to be reached by avoiding the use of samples. The universe has been explored to an extent of 89%. Between 1 June and 1 July 2022, the researchers visited HD centers and conducted in-person interviews to gather the data. The demographic data of both patients and caregivers were collected using a 16-item “Descriptive Information Form” and the “Zarit Caregiver Burden Scale (ZCBS)”. Results: The mean caregiving burden score of the participants was 47.53 ±13.87. Among the patients, 39.3% were between the ages of 41-60 and 40.2% were between the ages of 61-80. 85.7% of caregivers were 60 years old or younger. 75.7% of caregivers were women. There was a significant relationship between patient education level and caregiver burden. Caregivers with university degrees had a lower caregiving burden. The degree of caregiver burden was found to vary greatly depending on the caregiver’s age, marital status, occupation, and closeness to the patient. The caregiver burden was found to be favorably influenced by age and relationship with patient in the regression analysis of the caregivers’ demographic data. Conclusion: It was determined that the caregivers had a moderate level of caregiving burden.